Give a compliment! These pharmaceutical enterprises and technologies break the monopoly situation abroad

[China Pharmaceutical network industry trends] although the development of pharmaceutical technology in China started slowly, with the efforts and support of pharmaceutical enterprises and the national government, some gaps in pharmaceutical technology were gradually filled, which provided the impetus for the sound and rapid development of the domestic pharmaceutical industry It is not easy to break the monopoly of pharmaceutical technology Once the pharmaceutical enterprises succeed, they will not only have a certain say, but also bring benefits to enterprises and industries Next, I will take stock of the pharmaceutical technologies that have or will break the monopoly in China in recent years Ganli pharmaceutical industry is expected to break the monopoly of insulin market I expect that at present, the global insulin market and the domestic insulin market are basically dominated by three multinational pharmaceutical enterprises, Novo Nordisk, Lilly and Sanofi In order to break this situation, Ganli pharmaceutical has gradually caught up with the R & D pace of multinational enterprises in recent years, striving to compete with multinational pharmaceutical enterprises worldwide According to relevant data statistics, in 2015, Ganli pharmaceutical ranked the third in the market share of the third generation of insulin in China with 11.2% achievement, completing the 9% surpassing of Lilly In terms of overseas market, the market performance of Ganli pharmaceutical industry is also relatively bright, and it has achieved many phased results in developed countries such as Europe and the United States Some insiders pointed out that if Ganli pharmaceutical industry successfully passed the approval of FDA and successfully achieved the listing of glargine insulin in the United States, it will mean that domestic insulin is expected to further break the monopoly position of multinational pharmaceutical enterprises with high cost performance Truking technology breaks through the technical monopoly of pharmaceutical sub packaging equipment to participate in international competition In international technology and market competition, pharmaceutical sub packaging equipment is a high-tech, difficult and high-risk equipment with high technical threshold, and the core technology has been monopolized by international giants for a long time The technical gap of domestic industry in this field needs to be filled urgently For this reason, truking technology has invested a lot of R & D funds and time to tackle key problems It is reported that truking science and technology has achieved the crushing control of high-speed transport of thin-walled drug bottles, the control of small dose drug loading, and the on-line rapid detection control of micro foreign matters through more than ten years of continuous research and tackling key problems in production, teaching and research It has developed 119 kinds of high-precision sub packaging equipment for five categories of series drugs, breaking the technological monopoly, successfully realizing industrialization and participating in international competition After three years of hard work, Haibu medicine has broken through the bottleneck problem of research and development technology of Lac amide At present, there are more than 9 million epileptics in China, accounting for about half of the global epileptics Laconamide is a new type of antiepileptic drug, which has been listed and sold in Europe, the United States and Japan as early as possible, and the market is monopolized by foreign original research manufacturers I have learned that the R & D team of Beijing Haibu Pharmaceutical Technology Co., Ltd has broken through the technical bottleneck of the R & D of Lac amide after three years of hard work After testing, the key technical indicators of the drug are superior to USP and EP standards The product is expected to be put on the market in 2020 after joint declaration with pharmaceutical enterprises The domestic gene sequencing upstream domain monopoly revealed the breaking sign gene sequencing is a new gene detection technology, which can analyze and determine the whole gene sequence from blood or saliva, predict the possibility of suffering from a variety of diseases, individual behavior characteristics and reasonable behavior I have learned that the upstream of gene sequencing industry includes sequencer manufacturers, sequencing reagent consumables manufacturers and gene capture reagent manufacturers For many years, the domestic upstream field has been monopolized by foreign enterprises However, in recent years, this situation gradually shows signs of breaking down, and domestic gene technology enterprises begin to emerge, independently developing gene core technology comparable to foreign countries For example, the one-step capture technology developed by Lianchuan biology is a multi PCR based target library preparation technology, which can realize the whole process from specific target sequence capture to high-uniformity sequence library preparation in just a few minutes This technology not only breaks the monopoly situation of foreign countries, but also provides reference for other enterprises' research and development.